Merck Plans to Move HQ and 3 Dow Movers to Note
JPMorgan Chase & Co. (NYSE:JPM) on Tuesday announced that its 4th annual Technology Innovation Symposium will be held on Wednesday at the Rosewood Sand Hill in Menlo Park. The invitation-only event is to be an exchange of ideas aimed at promoting innovation and partnership between JPMorgan Chase and the Silicon Valley community.
The Coca-Cola Company (NYSE:KO) is among a group that also includes PepsiCo and Dr Pepper Snapple Group that on Monday introduced an initiative, starting in 2013, to start listing calorie counts on vending machines. Critics have said that the move is only aimed at avoiding demands for special taxes and other regulations, but it’s ostensibly in conjunction with a competition between Chicago and San Antonio municipal employees for a $5-million grant from the American Beverage Assn., an industry trade group. Many cities now face pressure from health advocates to help prevent the intake of fattening foods and drinks.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Merck & Co. (NYSE:MRK) intends to transfer its world headquarters within New Jersey from Whitehouse Station to its existing property in Summit, which currently hosts its manufacturing, research, animal health and consumer care operations and is also home to 1,800 people. The transition process is expected to begin in 2014 and should be completed mid-2015. Approximately 2,000 employees and contractors who are presently located at the Whitehouse Station world headquarters building either will transfer to the new facilities in Summit or to other nearby facilities such as those in Branchburg, and Cokesbury.
Microsoft Corporation (NASDAQ:MSFT) has sent invitations for a press event, at which its new Windows Phone 8 mobile operating system will be introduced. Near the end of the month, likely in the 29th, the next generation of WP is expected to be unveiled, perhaps at the London press event schedule for that date.
Don’t Miss: Is Pfizer’s Stock a Buy Now?